New York, NY 4/15/18—According to The Wall Street Journal, GE has shown no interest following Danaher’s overtures to the company about the possible acquisition of GE Healthcare’s Life Sciences business, and there have been no further discussions. Analysts estimate the deal would have been valued at more than $20 billion. The inquiry comes in the wake of GE’s strategic review of its businesses as a result of lower profits and share price declines. The Life Sciences business accounts for 24% of GE Healthcare’s $19 billion in annual revenue, according to the newspaper.

GE Healthcare Life Sciences supplies products related to bioprocessing, protein and cell science, contrast media and nuclear tracers, and cellular therapy. The business’s bioprocess and consumables offerings would have complimented two of Danaher’s faster growing products lines. However, observers pointed out in the article that Life Sciences is one of GE Healthcare’s most valued assets due to its profitabilty.